French drugmaker Sanofi has collaborated with DiCE Molecules to discover potential therapeutics based on unique small molecule discovery platform.

The potential new oral treatments would replace monoclonal antibodies for up to 12 targets that encompass all disease areas of strategic interest to Sanofi.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Sanofi Sunrise head Dr Kathy Bowdish said: "We are pleased to initiate this collaboration with DiCE and its unique technology platform, which brings the power of selection and enrichment to small molecule discovery.

"We hope this partnership will help deliver essential therapies against currently intractable disease targets, and help patients who otherwise have been unable to receive treatments outside of the inpatient setting.

"We are pleased to initiate this collaboration with DiCE and its unique technology platform, which brings the power of selection and enrichment to small molecule discovery."

"This initiative will allow our teams to combine their wealth of knowledge in drug discovery and further strengthens Sanofi’s commitment to open innovation."

Under the five-year collaboration, Sanofi will initially pay $50m to access DiCE’s technology, which selects and optimises drug-like ligands to any given target, beginning with libraries containing billions of individual molecules.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The technology is claimed to restore the libraries to their original ligand concentration after each round of screening, revealing the full landscape of binding molecules and allowing them to easily be selected for enhanced potency, selectivity, and drug-like properties through testing with proprietary assays.

This novel approach may address long-standing chemistry issues, in addition to enabling the replacement of monoclonal antibodies with orally administered medicines.

Sanofi will provide up to $184m in research, clinical and regulatory milestone payments.